NTLA240920C20000
- 2.50
- +0.15+6.38%
Intellia Therapeutics Newsroom
Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
Intellia Therapeutics Analyst Ratings
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
JonesTrading analyst Debanjana Chatterjee initiates coverage on $Intellia Therapeutics(NTLA.US)$ with a buy rating, and sets the target price at $41.According to TipRanks data, the analyst has a
Intellia Therapeutics: A Bullish Outlook on Gene Editing Innovation and Market Potential
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Stifel analyst Dae Gon Ha maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and adjusts the target price from $80 to $64.According to TipRanks data, the analyst has a success rate of 46.0%
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Is Maintained at Buy by Stifel
Express News | Intellia Therapeutics Inc : Stifel Cuts Target Price to $64 From $80
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Latest 6.7% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Intellia Therapeutics Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 52.7% and a total average return of 23.4%
Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
Maintaining Hold on Intellia Therapeutics Amid Financial Stability and Competitive Pressures
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Expert Ratings For Intellia Therapeutics